Background:

Ebselen (SPI-1005) is an inhibitor of HIV-1 capsid CTD dimerization[1]. Ebselen can permeate the blood-brain barrier and inhibit inositol monophosphatase (IMPase). Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties[2]. Ebselen inhibits QSOX1 enzymatic activity and has anticancer activity [3].

Ebselen (SPI-1005) inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process[1]. Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain[2].

参考文献:
[1]. Thenin-Houssier S, et al. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208.
[2]. Singh N, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320.
[3]. Hanavan PD, et al. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget. 2015 Jul 30;6(21):18418-28.